



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MTERFD3 siRNA (m): sc-149675

BACKGROUND

Members of the MTERF (mitochondrial transcription termination factor) family, including MTERF, MTERFD1, MTERFD2 and MTERFD3, are mitochondrial proteins that are thought to be transcription termination factors. MTERFD3 (MTERF domain containing 3), also known as MTERF2 (mitochondrial transcription termination factor 2) or MTERFL (mitochondrial transcription termination factor-like protein), is a 385 amino acid protein that is expressed in pancreas, heart, skeletal muscle and liver. The gene encoding MTERFD3 maps to human chromosome 12, which encodes over 1,100 genes and comprises approximately 4.5% of the human genome. Chromosome 12 is associated with a variety of diseases and afflictions, including hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome and trisomy 12p, which causes facial developmental defects and seizure disorders.

REFERENCES

1. Allen, T.L., Brothman, A.R., Carey, J.C. and Chance, P.F. 1996. Cytogenetic and molecular analysis in trisomy 12p. *Am. J. Med. Genet.* 63: 250-256.
2. Delgado Carrasco, J., Casanova Morcillo, A., Zabalza Alvillos, M. and Ayala Garcés, A. 2001. Achondrogenesis type II-hypochondrogenesis: radiological features. Case report. *An. Esp. Pediatr.* 55: 553-557.
3. Yokoyama, T., Nakatani, S. and Murakami, A. 2003. A case of Kniest dysplasia with retinal detachment and the mutation analysis. *Am. J. Ophthalmol.* 136: 1186-1188.
4. Chen, Y., Zhou, G., Yu, M., He, Y., Tang, W., Lai, J., He, J., Liu, W. and Tan, D. 2005. Cloning and functional analysis of human mTERFL encoding a novel mitochondrial transcription termination factor-like protein. *Biochem. Biophys. Res. Commun.* 337: 1112-1118.
5. Forzano, F., Lituania, M., Viassolo, A., Superti-Furga, V., Wildhardt, G., Zabel, B. and Faravelli, F. 2007. A familial case of achondrogenesis type II caused by a dominant COL2A1 mutation and "patchy" expression in the mosaic father. *Am. J. Med. Genet. A* 143: 2815-2820.
6. Pellegrini, M., Asin-Cayuela, J., Erdjument-Bromage, H., Tempst, P., Larsson, N.G. and Gustafsson, C.M. 2009. MTERF2 is a nucleoid component in mammalian mitochondria. *Biochim. Biophys. Acta* 1787: 296-302.
7. Lo, F.S., Luo, J.D., Lee, Y.J., Shu, S.G., Kuo, M.T. and Chiou, C.C. 2009. High resolution melting analysis for mutation detection for PTPN11 gene: applications of this method for diagnosis of Noonan syndrome. *Clin. Chim. Acta* 409: 75-77.
8. Spahr, H., Samuelsson, T., Hällberg, B.M. and Gustafsson, C.M. 2010. Structure of mitochondrial transcription termination factor 3 reveals a novel nucleic acid-binding domain. *Biochem. Biophys. Res. Commun.* 397: 386-390.
9. Hyvärinen, A.K., Pohjoismäki, J.L., Holt, I.J. and Jacobs, H.T. 2011. Overexpression of MTERFD1 or MTERFD3 impairs the completion of mitochondrial DNA replication. *Mol. Biol. Rep.* 38: 1321-1328.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: Mterfd3 (mouse) mapping to 10 C1.

PRODUCT

MTERFD3 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see MTERFD3 shRNA Plasmid (m): sc-149675-SH and MTERFD3 shRNA (m) Lentiviral Particles: sc-149675-V as alternate gene silencing products.

For independent verification of MTERFD3 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-149675A, sc-149675B and sc-149675C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

MTERFD3 siRNA (m) is recommended for the inhibition of MTERFD3 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor MTERFD3 gene expression knockdown using RT-PCR Primer: MTERFD3 (m)-PR: sc-149675-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.